GenScript Biotech Corporation and Ligand Pharmaceuticals Incorporated announced that they have entered into a strategic licensing agreement for Ligand's OmniAb® Platform, a multi-species antibody discovery platform, to generate highly diversified, fully human antibodies that are optimized in vivo for immunogenicity, manufacturability and efficacy. Under terms of the agreement, GenScript is now able to offer its global customers access to the OmniAb rodent platforms for high-quality, rapid, fully human antibody discovery services.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.34 HKD | +6.01% | +12.39% | -37.87% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.87% | 3.16B | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- 1548 Stock
- News Genscript Biotech Corporation
- GenScript Biotech Corporation and Ligand Pharmaceuticals Incorporated Enters into Global Omniab® Licensing Agreement